- Hypertrophic Cardiomyopathy (HCM)
- Eyecare
- Urothelial Carcinoma
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Asthma
- Atrial Fibrillation
- COVID-19
- Cardiovascular Diseases
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
U.S. Health Expenditure Expected to Reach $6.07 Trillion by 2027
Expenditures break down from managed care, out of pocket, investments and others. In 2022, the dominant share was held by managed care segment.
The U.S. health expenditure is forecasted to reach $6.07 trillion in 2027, experiencing growth at a CAGR of 5.61% in the next four years.
This data was found in the "U.S. Managed Care Market (Medicare, Medicaid, and Private Health Insurance): Insights & Forecast with Potential Impact of COVID-19" report.
Expenditures break down from managed care, out of pocket, investments and others. In 2022, the dominant share was held by managed care segment. This was being followed by out of pocket, investments and others.
The U.S. managed care market is forecasted to reach $4.12 trillion in 2027, experiencing growth at a CAGR of 6.11% up until 2027. Growth in the managed care market is supported by factors like rise in global healthcare expenditure, escalating urban population, rising geriatric population, increasing prevalence of cancer cases, favorable government initiatives, and growing adoption of healthcare insurance. However, the market growth is expected to be restrained by lack of knowledge and privacy.
The managed care market by payer can be broken down into Private Health Insurance, Medicare and Medicaid. In 2022, the dominant share of the US managed care market was held by Private Health Insurance, followed by Medicare and Medicaid. The faster growth in the net cost of health insurance is a primary reason for the acceleration in spending growth for private health insurance, Medicaid, and Medicare.
During Covid-19, there is a greater need for sophisticated healthcare, which raises healthcare expenditures. However, most people find it difficult to spend that much money on their healthcare needs, hence the managed care industry expanding during the time of COVID peak.
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Listen
Air Pollution May Negatively Affect Male Reproductive Health
November 30th 2023A potential mechanism by which air pollutants may affect reproductive health is by endocrine disruption. Air pollutants are made up of mixtures of particulate matter that may include endocrine disruptors, such as polycyclic aromatic hydrocarbons (PAHs) and heavy metals.
Read More
35th World AIDS Day Marks 20 Years of PEPFAR: Challenges and Strategies to Combat HIV/AIDS
November 29th 2023PEPFAR, having invested $100 billion and saved 25 million lives in the global fight against HIV/AIDS, faces Congressional hurdles in its reauthorization due to abortion debates. Despite widespread support and no evidence of abortion-related activities, the legislative process is at a standstill. Members of PEPFAR and authors of a recent editorial stress the significance of PEPFAR and advocate for integrating behavioral and social science into healthcare programs to achieve UNAIDS targets and address barriers in HIV/AIDS testing and treatment.
Read More
